{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:49:50Z","timestamp":1792450190942,"version":"4.5.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Chimeric antigen receptor (CAR)-T cell therapy has revolutionized the management of several life-threatening malignancies, often achieving durable sustained responses. The number of patients treated with this new class of cell-based therapy, along with the number of Food and Drug Association (FDA) approved indications, are growing significantly. Unfortunately Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) can often occur after treatment with CAR-T cells, and severe ICANS can be associated with significant morbidity and mortality. Current standard treatments are mainly steroids and supportive care, highlighting the need for early identification. In the last several years, a range of predictive biomarkers have been proposed to distinguish patients at increased risk for developing ICANS. In this review, we discuss a systematic framework to organize potential predictive biomarkers that builds on our current understanding of ICANS.<\/jats:p>","DOI":"10.3389\/fneur.2023.1110647","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T04:13:37Z","timestamp":1676261617000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":30,"title":["A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome"],"prefix":"10.3389","volume":"14","author":[{"given":"Omar H.","family":"Butt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beau M.","family":"Ances","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/d41573-022-00095-1'","article-title":"Landscape of cancer cell therapies: trends and real-world data","volume":"21","author":"Saez-Iba\u00f1ez","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"JULIET, investigatorstisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045.21.00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre open-label single-arm phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2022","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1470-204500591-X","article-title":"Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma. (ZUMA-5): a single-arm multicentre phase 2 trial","volume":"23","author":"Jacobson","year":"2022","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"All ZUMA 7 investigators and contributing kite members, axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"MKTE-X19 CART and cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736.21.01222-8","article-title":"RKTE","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736.20.31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas. (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/S0140-6736.22.00662-6","article-title":"InvestigatorsLisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma. (TRANSFORM): results from an interim analysis of an open-label randomised phase 3 trial","volume":"399","author":"Kamdar M Solomon","year":"2022","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","unstructured":"(idecabtagene vicleucel). Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple MyelomaPress Release"},{"key":"B15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-673600933-8","article-title":"SCiltacabtagene autoleucel a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jtct.0026","article-title":"Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.12","article-title":"Consensus grading for cytokine release s.yndrome and neurologic toxicity associated with immune effector","volume":"25","author":"Lee","year":"2019","journal-title":"Cells Biol Blood Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD.19 CAR, therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity Associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"key":"B21","doi-asserted-by":"publisher","first-page":"577027","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CART, Cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"J Blood Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR- cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B25","doi-asserted-by":"publisher","first-page":"355ra","DOI":"10.1126\/scitranslmed.aaf8621","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","volume":"8","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/JCO.728519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T, cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J Clin Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"7024","DOI":"10.1200\/JCO.2017.35.15_suppl.7024","article-title":"Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19\u201328z CAR T cells in adult patients with relapsed B ALL","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"B33","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B, cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/blood","article-title":"Toxicity and response after CD19-specific CAR, T-cell therapy in pediatric\/young adult relapsed\/refractory ball","volume":"134","author":"Curran","year":"2019","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation management and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome. (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"E427","DOI":"10.1002\/ajh.26330","article-title":"Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B, cell lymphoma patients treated with axicabtagene ciloleucel","volume":"96","author":"Wudhikarn","year":"2021","journal-title":"Am J Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jtct.07011","article-title":"Patterns of use outcomes and resource utilization among recipients of commercial axicabtagene ciloleucel and tisagenlecleucel for relapsed\/refractory aggressive B, cell lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant Cell Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Barba PGETH, GELTAMO, Spanish groups, Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD.19 CAR, T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"M\u00f6hn","year":"2022","journal-title":"Neurol Res Pract"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1182\/bloodadvances.2021006144","article-title":"Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CART. cell treatment","volume":"6","author":"Schoeberl","year":"2022","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e223738","DOI":"10.1001\/jamaoncol.2022.3738","volume":"5","author":"Butt","year":"2022","journal-title":"JAMA"},{"key":"B47","doi-asserted-by":"publisher","first-page":"3376","DOI":"10.1182\/blood.2021013733","article-title":"Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL","volume":"139","author":"Qi","year":"2022","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/2326-6066.CIR-22-0418","article-title":"Hypophosphatemia due to increased effector cell metabolic activity is associated with neurotoxicity symptoms in CD19-targeted CART cell therapy","volume":"3","author":"Tang","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"8119","DOI":"10.1182.\/bloodadvances.2022008119","article-title":"Increase during neurotoxicity from high baseline levels in pediatric CD.19-CAR, T-cell patients","volume":"3","author":"Gust","year":"2022","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood.2019004162","article-title":"Outcomes of older patients in ZUMA, 1 a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"135","author":"Neelapu","year":"2020","journal-title":"Blood"},{"key":"B51","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3324\/haematol.2019.243246","article-title":"Impact and safety of chimeric antigen receptor T-cell therapy in older vulnerable patients with relapsed\/refractory large B-cell lymphoma","volume":"106","author":"Lin","year":"2021","journal-title":"Haematologica"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1007\/s00277-021-04560-6","article-title":"Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CART-cell therapy","volume":"100","author":"Iacoboni","year":"2021","journal-title":"Ann Hematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00259-014-2822-7","article-title":"Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma","volume":"41","author":"Sasanelli","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2020001900","article-title":"High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Dean","year":"2020","journal-title":"Blood Adv"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.bbmt.2019.02.008","article-title":"Role of fluorodeoxyglucose positron emission tomography\/computed tomography in predicting the adverse effects of chimeric antigen receptor T, cell therapy in patients with non-hodgkin lymphoma","volume":"25","author":"Wang","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"B56","doi-asserted-by":"publisher","first-page":"E50","DOI":"10.3174\/ajnr.A6184","article-title":"Chimeric antigen receptor T-cell neurotoxicity neuroimaging: more than meets the eye","volume":"40","author":"Gust","year":"2019","journal-title":"AJNR Am J Neuroradiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"key":"B58","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1161\/01.RES.0000066881.04116.45","article-title":"Tie-ing the antiinflammatory effect of angiopoietin-1 to inhibition of NF-kappa B","volume":"92","author":"Jeon","year":"2003","journal-title":"Circ Res"},{"key":"B59","doi-asserted-by":"publisher","first-page":"5962","DOI":"10.1038\/ncomms6962","article-title":"Endothelial destabilization by angiopoietin-2 via integrin \u03b21 activation","volume":"6","author":"Hakanpaa","year":"2015","journal-title":"Nat Commun"},{"key":"B60","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin,-TIE, pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CART and cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Adv"},{"key":"B62","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/cpt.2040","article-title":"Model-based cellular kinetic analysis of chimeric antigen receptor-T, cells in humans","volume":"109","author":"Liu","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL.-,1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045.12.70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e0139598","DOI":"10.1371\/journal.pone.0139598","article-title":"Serum IL-10 predicts worse outcome in cancer patients: a meta-analysis","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS ONE"},{"key":"B68","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.immuni.03020","article-title":"O'Garra A. IL-10 Family Cytokines IL-10 and IL-22: from basic science to clinical","volume":"50","author":"Ouyang","year":"2019","journal-title":"Translat Immun."},{"key":"B69","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/bies.201300004","article-title":"Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-\u03b3-mediated CD8","volume":"35","author":"Mumm","year":"2013","journal-title":"Bioessays"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e005459","DOI":"10.1136\/jitc-2022-005459","article-title":"Forecasting immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor t-cell therapy","volume":"10","author":"Amidi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive Serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell all receiving CAR, T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1110647\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T04:13:42Z","timestamp":1676261622000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1110647\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":71,"alternative-id":["10.3389\/fneur.2023.1110647"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1110647","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"article-number":"1110647"}}